Sandoz granted novel biosimilars approval
The approval authorises the interchangeability of denosumab biosimilars in the…
The approval authorises the interchangeability of denosumab biosimilars in the US to treat primary and secondary bone loss.
List view / Grid view
The approval authorises the interchangeability of denosumab biosimilars in the…
The approval authorises the interchangeability of denosumab biosimilars in the US to treat primary and secondary bone loss.
Sandoz’s Tyruko (natalizumab-sztn) is now the first US Food and…
Sandoz’s Tyruko (natalizumab-sztn) is now the first US Food and Drug Administration (FDA)-approved biosimilar to Tysabri (natalizumab) injection for relapsing forms of multiple sclerosis.